Comparative Pharmacology
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus METHYLIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus METHYLIN ER.
AMPHETAMINE SULFATE vs METHYLIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Category D/X
Category C
CNS Stimulant
CNS Stimulant